Welcome to the Illinois Medical Oncology Society

Illinois Medical Oncology Society (IMOS)

Formed on July 29, 1989, the Illinois Medical Oncology Society (IMOS) represents the common interests of a majority of the oncologists treating cancer in Illinois. As the oncology society in Illinois, we strive to provide our members with innovative resources to help them stay ahead of the shifting healthcare landscape and challenges that directly impact the high-quality care their patients deserve.

The Illinois Medical Oncology Society now offers FREE  memberships to oncologists and allied oncology professionals.

 

Find out more about membership

 

The IMOS board would also like to hear from you (all levels and types of members and potential members) about things you’d like to see for 2018- 2019 and how we can best serve your needs.

 

We are a State Affiliate of the American Society of Clinical Oncology.

Our Mission

We strive to promote the highest professional standards of oncology in the State of Illinois.  We create educational experiences for our members to exchange information to increase the quality of care for our patients. We act as a patient advocate to assure that patients have access to the best available care; and support and encourage clinical research against cancer.

Find out more

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Find out more

COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Find out more

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments.

Find out more

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease

Click here for more.

 


 

News

2019 Spring Meeting Presentations are now available in the members area.  Please log in to view.


September 13 - 14, 2019
Lincolnshire Marriott Resort
Ten Marriott Drive · Lincolnshire, Illinois 60069 USA
1-847-634-0100

Click here to make your hotel reservations online*
*Make sure to mention the IMOS Fall meeting to get your conference rate.

Click here for registration information

Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule. 

The CMS fact sheet is available here.  In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.

Click here for more

Denial Rates and Days to Pay for Cancer Drugs: Commercial Health Plan Report Card

Office-administered oncology drugs given in the community setting face stiff reimbursement challenges when billing commercial plans; while Medicare has emerged as the gold standard for both predictable payment and timeliness. 

Click here for More.

 

Learn more about the big changes to the ASH Scholar Award program.
More people are now eligible for the ASH Scholar Awards than ever before. The new Fellow to Faculty Scholar Award offers financial support to those preparing to compete for independent faculty-level positions in the next two to three years.

Click here for more.